WINNER MEDICAL CO., LTD. Financials Winner Medical Co., Ltd.
Equities
300888
CNE1000047Z8
Medical Equipment, Supplies & Distribution
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 31.5 CNY | +1.55% |
|
+0.64% | -15.44% |
| Apr. 26 | Winner Medical's Q1 Profit Drops 52% as Operating Income Slides 19% | MT |
| Apr. 26 | Winner Medical's 2023 Profit Shrinks 65%, Operating Income Falls 28% | MT |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 70,798 | 35,164 | 30,011 | 21,889 | 18,394 | - | - |
| Enterprise Value (EV) 1 | 70,798 | 35,164 | 30,011 | 21,889 | 18,394 | 18,394 | 18,394 |
| P/E ratio | 17 x | 28.3 x | 18.3 x | 38 x | 20.3 x | 14.4 x | 15.8 x |
| Yield | 1.08% | 1.09% | 2.66% | 1.34% | 2.27% | 2.68% | 2.73% |
| Capitalization / Revenue | 5.65 x | 4.38 x | 2.64 x | 2.67 x | 2.08 x | 1.73 x | 1.78 x |
| EV / Revenue | 5.65 x | 4.38 x | 2.64 x | 2.67 x | 2.08 x | 1.73 x | 1.78 x |
| EV / EBITDA | 14.8 x | 18.4 x | 13 x | 18.4 x | 12.3 x | 10.7 x | 10.8 x |
| EV / FCF | - | 110 x | 16.2 x | 52.3 x | 8.09 x | 22.8 x | 19.9 x |
| FCF Yield | - | 0.91% | 6.16% | 1.91% | 12.4% | 4.38% | 5.02% |
| Price to Book | 6.77 x | 3.29 x | 2.61 x | 1.92 x | 1.53 x | 1.35 x | 1.36 x |
| Nbr of stocks (in thousands) | 597,089 | 597,089 | 587,633 | 587,633 | 583,938 | - | - |
| Reference price 2 | 118.6 | 58.89 | 51.07 | 37.25 | 31.50 | 31.50 | 31.50 |
| Announcement Date | 4/19/21 | 4/21/22 | 4/24/23 | 4/24/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 4,575 | 12,534 | 8,037 | 11,351 | 8,185 | 8,828 | 10,637 | 10,339 |
| EBITDA 1 | - | 4,789 | 1,908 | 2,316 | 1,188 | 1,496 | 1,718 | 1,702 |
| EBIT 1 | - | 4,532 | 1,476 | 1,977 | 818 | 1,154 | 1,602 | 1,477 |
| Operating Margin | - | 36.16% | 18.36% | 17.41% | 9.99% | 13.07% | 15.06% | 14.29% |
| Earnings before Tax (EBT) 1 | - | 4,502 | 1,463 | 1,920 | 749.8 | 1,132 | 1,575 | 1,472 |
| Net income 1 | 546.3 | 3,810 | 1,239 | 1,651 | 580.4 | 1,099 | 1,296 | 1,174 |
| Net margin | 11.94% | 30.4% | 15.42% | 14.54% | 7.09% | 12.45% | 12.19% | 11.35% |
| EPS 2 | 1.036 | 6.993 | 2.079 | 2.786 | 0.9800 | 1.550 | 2.192 | 1.997 |
| Free Cash Flow 1 | - | - | 319.4 | 1,847 | 418.3 | 2,273 | 805 | 923 |
| FCF margin | - | - | 3.97% | 16.27% | 5.11% | 25.75% | 7.57% | 8.93% |
| FCF Conversion (EBITDA) | - | - | 16.74% | 79.75% | 35.2% | 151.94% | 46.86% | 54.23% |
| FCF Conversion (Net income) | - | - | 25.77% | 111.92% | 72.07% | 206.76% | 62.1% | 78.62% |
| Dividend per Share 2 | - | 1.286 | 0.6429 | 1.357 | 0.5000 | 0.7150 | 0.8450 | 0.8600 |
| Announcement Date | 8/27/20 | 4/19/21 | 4/21/22 | 4/24/23 | 4/24/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 S1 | 2021 Q4 | 2022 Q1 | 2022 Q3 |
|---|---|---|---|---|
| Net sales 1 | 4,060 | 2,217 | - | 2,484 |
| EBITDA | - | - | - | - |
| EBIT | - | - | - | - |
| Operating Margin | - | - | - | - |
| Earnings before Tax (EBT) | - | - | - | - |
| Net income | 761 | 135.3 | 357.1 | - |
| Net margin | 18.75% | 6.1% | - | - |
| EPS | - | - | 0.6000 | - |
| Dividend per Share | - | - | - | - |
| Announcement Date | 9/29/21 | 4/21/22 | 4/21/22 | 10/24/22 |
1CNY in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | - | 319 | 1,847 | 418 | 2,273 | 805 | 923 |
| ROE (net income / shareholders' equity) | - | 64.7% | 11.8% | 14.9% | 5.03% | 8.46% | 9.4% | 8.62% |
| ROA (Net income/ Total Assets) | - | 43.5% | 9.44% | 9.91% | - | 5.48% | 6.1% | 6.46% |
| Assets 1 | - | 8,767 | 13,134 | 16,657 | - | 20,049 | 21,262 | 18,187 |
| Book Value Per Share 2 | - | 17.50 | 17.90 | 19.60 | 19.40 | 20.60 | 23.30 | 23.10 |
| Cash Flow per Share 2 | - | 7.980 | 1.460 | 5.000 | 1.790 | 2.240 | 3.010 | 2.410 |
| Capex 1 | - | 327 | 552 | 1,136 | 645 | 474 | 426 | 317 |
| Capex / Sales | - | 2.61% | 6.87% | 10.01% | 7.88% | 5.36% | 4.01% | 3.06% |
| Announcement Date | 8/27/20 | 4/19/21 | 4/21/22 | 4/24/23 | 4/24/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
31.5
CNY
Average target price
37.77
CNY
Spread / Average Target
+19.89%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -15.44% | 2.51B | |
| +9.48% | 27.38B | |
| -30.22% | 3.08B | |
| +18.49% | 2.45B | |
| +7.04% | 2.09B | |
| -4.11% | 2.05B | |
| +1.67% | 1.55B | |
| +1.22% | 1.29B | |
| +23.78% | 1.23B | |
| +6.87% | 1.13B |
- Stock Market
- Equities
- 300888 Stock
- Financials Winner Medical Co., Ltd.